Abstract
Hypertension increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the risk of new-onset T2DM and offers renal protection. Using a MEDLINE search, we identified multiple trials that reported the incidence of T2DM in patients taking inhibitors of RAAS. In this review, we will discuss the RAAS as a potential target in diabetes prevention and the mechanisms through which inhibitors of this system achieve such an important effect. We will also shed light on the beneficial cardiovascular and renal effects of RAAS blockade. Although multiple studies have demonstrated that inhibitors of RAAS, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, can reduce the incidence of T2DM, randomized controlled studies are still needed to further elucidate their exact role in diabetes prevention.
| Original language | English |
|---|---|
| Pages (from-to) | 1157-1166 |
| Number of pages | 10 |
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 10 |
| Issue number | 12 |
| DOIs | |
| State | Published - 2008 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. / Abuissa, Hussam; O'Keefe, James.
In: Diabetes, Obesity and Metabolism, Vol. 10, No. 12, 2008, p. 1157-1166.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection
AU - Abuissa, Hussam
AU - O'Keefe, James
PY - 2008
Y1 - 2008
N2 - Hypertension increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the risk of new-onset T2DM and offers renal protection. Using a MEDLINE search, we identified multiple trials that reported the incidence of T2DM in patients taking inhibitors of RAAS. In this review, we will discuss the RAAS as a potential target in diabetes prevention and the mechanisms through which inhibitors of this system achieve such an important effect. We will also shed light on the beneficial cardiovascular and renal effects of RAAS blockade. Although multiple studies have demonstrated that inhibitors of RAAS, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, can reduce the incidence of T2DM, randomized controlled studies are still needed to further elucidate their exact role in diabetes prevention.
AB - Hypertension increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the risk of new-onset T2DM and offers renal protection. Using a MEDLINE search, we identified multiple trials that reported the incidence of T2DM in patients taking inhibitors of RAAS. In this review, we will discuss the RAAS as a potential target in diabetes prevention and the mechanisms through which inhibitors of this system achieve such an important effect. We will also shed light on the beneficial cardiovascular and renal effects of RAAS blockade. Although multiple studies have demonstrated that inhibitors of RAAS, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, can reduce the incidence of T2DM, randomized controlled studies are still needed to further elucidate their exact role in diabetes prevention.
UR - http://www.scopus.com/inward/record.url?scp=55549124195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55549124195&partnerID=8YFLogxK
U2 - 10.1111/j.1463-1326.2008.00898.x
DO - 10.1111/j.1463-1326.2008.00898.x
M3 - Review article
C2 - 18494810
AN - SCOPUS:55549124195
VL - 10
SP - 1157
EP - 1166
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 12
ER -